SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-010014
Filing Date
2024-03-15
Accepted
2024-03-15 08:10:31
Documents
15
Period of Report
2024-03-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43111
2 ex99-1.htm EX-99.1 65796
  Complete submission text file 0001493152-24-010014.txt   295223

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ensc-20240315.xsd EX-101.SCH 3012
4 XBRL LABEL FILE ensc-20240315_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE ensc-20240315_pre.xml EX-101.PRE 22357
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3672
Mailing Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037
Business Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037 (858) 263-4196
Ensysce Biosciences, Inc. (Filer) CIK: 0001716947 (see all company filings)

IRS No.: 822755287 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38306 | Film No.: 24752543
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)